Table 2.
Values for pulmonary carbon dioxide (), sodium (Na+), potassium (K+) and chloride (Cl−) levels prior to the start of the protocol (i.e. baseline conditions) and after the termination of the protocol (i.e. 60 min after recording)
| (mmHg) | Na+ (mmol L−1) | K+ (mmol L−1) | Cl− (mmol L−1) | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Post | Baseline | Post | Baseline | Post | Baseline | Post | |
| Hypoxia groups | ||||||||
| Time control | 43.0 ± 1.0 | 42.4 ± 0.5 | 145.4 ± 1.5 | 143.6 ± 1.5 | 4.2 ± 0.2 | 4.2 ± 0.2 | 112.4 ± 1.2 | 111.8 ± 1.0 |
| Losartan control | 42.3 ± 1.2 | 42.8 ± 0.9 | 142.0 ± 1.1 | 142.8 ± 1.3 | 4.1 ± 0.2 | 4.1 ± 0.1 | 110.5 ± 0.9 | 111.3 ± 1.1 |
| AIH + Saline | 41.2 ± 0.7 | 42.8 ± 0.7 | 142.2 ± 0.7 | 140.6 ± 0.7 | 3.9 ± 0.4 | 3.9 ± 0.3 | 109.4 ± 0.5 | 110.2 ± 0.4 |
| AIH + Losartan | 40.0 ± 0.7 | 41.0 ± 1.0 | 140.8 ± 0.9 | 141.2 ± 1.0 | 4.3 ± 0.2 | 4.2 ± 0.1 | 111.4 ± 1.2 | 112.8 ± 0.8 |
| AIH + Aliskiren | 41.5 ± 1.7 | 40.8 ± 1.6 | 142.0 ± 1.5 | 141.3 ± 0.8 | 3.8 ± 0.2 | 3.7 ± 0.1 | 109.5 ± 0.6 | 110.5 ± 0.9 |
| AIH + Sham | 41.3 ± 1.5 | 41.8 ± 1.4 | 141.3 ± 0.9 | 141.4 ± 0.7 | 3.7 ± 0.2 | 3.7 ± 0.2 | 110.0 ± 1.2 | 111.7 ± 1.2 |
| AIH + CBD | 40.3 ± 0.9 | 41.3 ± 1.3 | 139.8 ± 1.0 | 140.1 ± 0.7 | 4.2 ± 0.1 | 4.2 ± 0.1 | 112.0 ± 1.3 | 111.3 ± 0.6 |
| AIH + SFOvehicle | 41.0 ± 1.6 | 42.0 ± 0.9 | 139.3 ± 1.5 | 139.3 ± 0.5 | 4.1 ± 0.2 | 4.1 ± 0.2 | 109.0 ± 0.9 | 109.5 ± 0.9 |
| AIH + SFOmiss | 41.4 ± 1.4 | 41.0 ± 1.5 | 140.8 ± 1.1 | 141.2 ± 0.7 | 4.0 ± 0.1 | 4.0 ± 0.1 | 112.2 ± 1.0 | 111.4 ± 0.4 |
| AIH + SFOiso | 39.0 ± 1.5 | 40.5 ± 0.8 | 139.4 ± 1.5 | 140.3 ± 0.9 | 4.1 ± 0.2 | 4.2 ± 0.1 | 111.4 ± 1.4 | 111.0 ± 0.7 |
| AIH + CBD∙SFOiso | 41.3 ± 1.5 | 42.3 ± 0.7 | 141.2 ± 1.0 | 143.2 ± 0.9 | 4.1 ± 0.2 | 4.1 ± 0.1 | 110.2 ± 1.0 | 109.5 ± 1.0 |
| Drug treatment groups | ||||||||
| Int.Saline | 41.5 ± 1.7 | 40.8 ± 1.5 | 140.8 ± 0.8 | 140.3 ± 0.3 | 4.1 ± 0.2 | 4.1 ± 0.5 | 111.3 ± 1.7 | 110.3 ± 0.5 |
| Int.Ang II | 41.4 ± 1.1 | 40.4 ± 0.5 | 143.8 ± 2.4 | 141.6 ± 1.4 | 3.7 ± 0.5 | 3.7 ± 0.3 | 114.4 ± 2.8 | 111.6 ± 1.6 |
| Int.Ang II + Losartan | 42.3 ± 1.3 | 41.0 ± 0.7 | 145.3 ± 2.4 | 144.0 ± 1.5 | 3.6 ± 0.6 | 3.6 ± 0.3 | 111.5 ± 2.1 | 111.8 ± 1.5 |
| Int.Ang II + Sham | 40.6 ± 0.9 | 39.8 ± 0.6 | 141.8 ± 0.8 | 141.4 ± 0.6 | 4.0 ± 0.3 | 4.1 ± 0.2 | 108.6 ± 1.5 | 108.6 ± 1.4 |
| Int.Ang II + CBD | 40.8 ± 1.6 | 40.8 ± 0.7 | 141.2 ± 1.2 | 141.6 ± 0.7 | 4.0 ± 0.3 | 4.1 ± 0.2 | 111.8 ± 2.0 | 111.6 ± 1.3 |
| Int.Ang II + SFOiso | 39.3 ± 1.1 | 39.8 ± 0.9 | 142.0 ± 0.7 | 141.5 ± 0.6 | 4.4 ± 0.0 | 4.4 ± 0.0 | 110.3 ± 1.1 | 109.8 ± 0.9 |
| Int.Ang II + CBD∙SFOiso | 40.5 ± 0.9 | 40.5 ± 0.8 | 142.0 ± 1.4 | 141.3 ± 1.1 | 4.0 ± 0.2 | 4.0 ± 0.1 | 110.8 ± 1.3 | 111.3 ± 0.9 |
| Int.Phenylephrine | 40.7 ± 1.8 | 39.7 ± 0.9 | 139.3 ± 2.2 | 140.7 ± 0.3 | 4.4 ± 0.2 | 4.3 ± 0.0 | 109.0 ± 3.8 | 110.3 ± 2.9 |
| Int.Phenylephrine + Aliskiren | 42.7 ± 0.9 | 42.7 ± 0.6 | 139.0 ± 2.5 | 139.8 ± 2.4 | 4.5 ± 0.1 | 4.5 ± 0.1 | 111.3 ± 0.3 | 111.7 ± 0.5 |
| Int.Sodium nitroprusside | 40.0 ± 2.5 | 40.0 ± 1.3 | 142.3 ± 0.3 | 142.2 ± 0.5 | 4.4 ± 0.2 | 4.4 ± 0.2 | 110.7 ± 1.8 | 109.6 ± 1.9 |
Values are in mean ± SEM. One‐way ANOVA with Holm–Šidák correction was used for multiple comparisons between groups for baseline pulmonary carbon dioxide (), sodium (Na+), potassium (K+) and chloride (Cl−) levels. Two‐way ANOVA with Holm–Šidák correction was used for multiple comparisons between baseline and post‐protocol values for values. There were no differences between all comparisons.